NKGen Biotech Inc. (OTC: NKGN) announced data from combined Phase 1 trials of its troculeucel therapy showing cognitive improvements in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE